Toll-like receptor-4 (TLR4) is a primary receptor of the innate immune reaction and compelling evidence demonstrates its involvement in the pathogenesis of atherosclerosis and stroke. TLR4 is constitutively expressed on monocytes and endothelial cells; it is highly expressed in atherosclerotic plaques and in peripheral blood of patients after ischemic stroke. Polymorphisms in the promoter region that alter the transcriptional regulation of this gene may represent genetic risk factors involved in the predisposition to atherosclerotic disease. In this study we investigated the effect on TLR4 gene expression of three polymorphisms in the upstream regulatory region at positions À1607T4C/rs10759932, À2026A4G/rs1927914 and À2604G4A/rs10759931 in peripheral blood of atherosclerotic patients. RNA from individuals homozygous for the À2604A allele showed a lower expression of the gene when compared to patients carrying the counterparts GG þ GA. Electrophoretic mobility shift assays showed differences in the electrophoretic mobility of the DNA-nuclear protein complexes formed by the G4A variants, suggesting that the two alleles differ in their binding affinity to transcriptional factors.
INTRODUCTION
Stroke is the third cause of death and the first cause of permanent disability in developed countries. Up to 15% of ischemic events are associated with atherosclerotic carotid stenosis. 1 Toll-like receptor-4 (TLR4), the primary receptor of the innate immune system, is crucial for endotoxin signaling and is a limiting factor for the innate response to bacterial liposaccharide (LPS). 2 Besides LPS various endogenous ligands for TLR4 have been identified and some have been proposed to function in the process of atherogenesis. [3] [4] [5] TLR4 is expressed in circulating monocytes, 6 and in a number of different cell types present in the plaques of atherosclerotic patients. 7 There is evidence that overexpression of this gene is involved in initiation and progression of atherosclerosis. 8 Activation of TLR4 initiates an intracellular signaling cascade, leading to the activation of nuclear factor (NF)-kB transcriptional factor, which promotes the induction of a proinflammatory response, including the release of antimicrobial peptides, inflammatory cytokines and chemokines. 9 Genomic variations that alter TLR4 gene expression may represent genetic risk factors involved in the predisposition to atherosclerosis and ischemic events. 10 The aim of this study is to investigate if polymorphisms in the TLR4 gene promoter region may influence gene expression in peripheral blood of atherosclerotic patients.
RESULTS AND DISCUSSION
Consecutive patients undergoing carotid endarterectomy at Verona University Hospital were enrolled, with either a recently symptomatic or an asymptomatic internal carotid artery (ICA) stenosis, as described elswhere. 11 Controls were individuals presenting no sign of atherosclerotic plaques at ecodoppler examination. DNA and total RNA were extracted from peripheral blood samples. ICA stenosis degree was stratified into 50-69%, 70-80% and 480%. Clinical severity of stroke was rated through the National Institute of Health Stroke Scale (NIHSS). 12 Functional polymorphisms À1607T4C, À2026A4G and À2604G4A 13 were genotyped by PCR-restriction fragment length polymorphism (Supplementary Table 2 ), and gene expression was performed by Real-time PCR as described 11 (Supplementary Table 3) . By in silico analysis, other single-nucleotide polymorphisms present in the region do not alter transcription-binding sites or are in strong linkage disequilibrium with the selected ones. 13 Gene expression differences between genotypes of polymorphisms were assessed by analysis of variance test. Dominant and recessive models were tested by the Student's t-test. Single analysis was adjusted for multiple tests (Po0.02). Fisher's exact test showed no significant difference between symptomatic and asymptomatic patients for clinical variables (except for sex; Supplementary Table 1) . Allele frequencies and genotype distribution are shown in Supplementary Table 4. TLR4 expression was significantly higher in symptomatic patients compared with asymptomatic and controls. No difference between asymptomatic and controls was observed ( Supplementary  Figure 1) .
TLR4 gene expression showed no correlation with age or NHISS (data not shown).
A trend of association of TLR4 gene expression with stenosis degree was observed in symptomatic patients (P ¼ 0.05, Figure 1) . The most severe grade of stenosis showed the highest TLR4 gene expression, suggesting that TLR4 expression could represent a marker of disease severity in this group of patients.
Gene expression showed no significant differences between the different genotypes of variants 1607T4C and À2026A4G (data not shown). Polymorphism À2604G4A showed a lower level of TLR4 expression of the genotype À2604AA (0.86 ± 0.58 (AA) vs 1.58 ± 1.9 (GA þ GG), Po0.02; Figure 2 ). This difference was also observed among groups when patients were divided into symptomatic, asymptomatic and control group. Consistently, linear regression analysis demonstrated that this effect was independent from disease status, indicating that both disease and genotype may influence TLR4 expression.
The lower gene expression observed in individuals carrying the À2604AA genotype is consistent with previous studies, 14 in which vector constructs containing the À2604A variant, which creates a putative GATA-2 transcription-binding site, showed lower promoter activity when transfected into A498 renal carcinoma cells. To determine whether this polymorphism alters the transcription-binding site for GATA-2, electrophoretic mobility shift assay (EMSA) was performed as described. 14 In brief, we used radiolabeled oligonucleotide probes containing either À2604G or À2604A probes (Figure 3 ). On incubation of the probe À2604A with cell nuclear extracts, two distinct prevalent complexes (indicated as C1 and C2, in Figure 3 ) were revealed. The specificity of the binding reaction was confirmed by full competition of the non-labeled GATA oligonucleotides compared to the almost absence competition of nonlabeled NF-kB consensus binding site oligonucleotides. In the presence of excess of the non-labeled À2604A fragment, the complexes C1 and C2 were competed away too, demonstrating the specificity for the probe. Compared to A allele, the 2604G probe showed a different electrophoretic mobility of the C1 complex (Figure 3) , indicating that the À2604G4A polymorphism can affect the binding affinity of the TLR4 promoter to transcription factors. The pattern of complexes resulted similar to that obtained by a consensus GATA sequence, suggesting that members of the GATA family participate in the complex. The supershift analyses in presence of the antibody directed to GATA-2 transcription factor (Santa Cruz Biotechnology, Santa Cruz, CA, USA) failed to detect a mobility shift (Figure 3) , indicating that the sequence might be recognized by GATA family transcription factors other than GATA-2.
Considering that À2604A allele shows a lower level of TLR4 gene expression, and that EMSA results showed a different mobility pattern of À2604G4A variants, we can infer that nuclear factor/s binding to the region covering À2604G4A polymorphism may function as modulator(s) for TLR4 transcription, probably due to the contribution of an undetermined member of the GATA zinc-finger transcription factors. Indeed, GATA transcription factors have been demonstrated to have a crucial role in the regulation of epithelial innate immune responses. [15] [16] [17] In conclusion, TLR4 is upregulated in stroke patients, indicating that TLR4 may be involved in the inflammation process leading to the ischemic event.
The presence of allele À2604A is associated with lower levels of TLR4 gene expression. This difference could be due to different transcription factors binding capacity of variants of the À2604G4A polymorphism.
Further case/control studies in larger populations should verify if TLR4 variant À2604A4G represents a genetic marker for susceptibility to atherosclerotic plaque development and progression. 
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